Borrelia spielmanii-Associated Neuroborreliosis in Patient Receiving Rituximab, Belgium.

Carette, Timothée;Lebrun, Louisien;Kabamba-Mukadi, Benoît;Raymackers, Jean-Marc;Bayart, Jean-Louis
(2025) Emerging infectious diseases — Vol. 31, n° 2, p. 341-344 (2025)

Files

No attached file found for this publication.

Details

Authors
Abstract
A 58-year-old woman in Belgium with a history of follicular lymphoma treated with rituximab sought care for a rapid sensory-motor deficit. Seronegative neuroborreliosis caused by Borrelia spielmanii was diagnosed, likely related to humoral deficiency. High CXC motif chemokine ligand 13 levels and PCR confirmed the diagnosis. Ceftriaxone treatment led to full recovery.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Carette, T., Lebrun, L., Kabamba-Mukadi, B., Raymackers, J.-M., & Bayart, J.-L. (2025). Borrelia spielmanii-Associated Neuroborreliosis in Patient Receiving Rituximab, Belgium. Emerging infectious diseases, 31(2), 341-344. https://doi.org/10.3201/eid3102.240777 (Original work published 2025)